Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...

Principal Financial Group Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 25.7 ...

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares ...

Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...

Halozyme Therapeutics (HALO) announced that Takeda (TAK) received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and ...

(RTTNews) - Halozyme Therapeutics (HALO) announced that Takeda received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and Welfare for patients with agammaglobulinemia ...

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...

On Monday, H.C. Wainwright reaffirmed a Buy rating and a price target of $68.00 on Halozyme Therapeutics (NASDAQ:HALO). The endorsement follows the recent FDA approval of a subcutaneous (SC ...